Pharmakin

Pharmakin is a clinical-stage biotechnology company based in Beijing, China, specializing in the discovery and development of next-generation small molecule kinase inhibitors. The company's primary focus is on targeting the Janus kinase (JAK) family and Tyrosine kinase 2 (TYK2) to treat a variety of autoimmune and inflammatory diseases. Its lead candidate, PK-101, is a highly selective TYK2 inhibitor currently in Phase 2 clinical trials for psoriasis and atopic dermatitis, designed to offer improved safety over non-selective JAK inhibitors. Pharmakin's pipeline also includes PK-201, a JAK1-selective inhibitor, and PK-501, which targets JAK3 and TEC kinases. By leveraging its proprietary drug discovery platform, Pharmakin aims to develop best-in-class therapies for global markets. The company is backed by prominent venture capital firms and led by an experienced management team with deep expertise in medicinal chemistry.